Taro Pharmaceutical Industries Ltd (TARO)

105.66
0.71 0.68
NYSE : Health Care
Prev Close 104.95
Open 104.32
Day Low/High 103.58 / 105.98
52 Wk Low/High 92.28 / 157.99
Volume 100.83K
Avg Volume 248.80K
Exchange NYSE
Shares Outstanding 41.03M
Market Cap 4.33B
EPS 12.60
P/E Ratio 8.32
Div & Yield N.A. (N.A)

Latest News

Taro Announces Appointment Of Interim CEO

Taro Announces Appointment Of Interim CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that its Board of Directors has appointed Mr.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Taro Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 27, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Taro Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 27, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Taro Pharmaceutical Industries Ltd.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Taro Pharmaceutical Industries Ltd. To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Taro Pharmaceutical Industries Ltd. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Taro Announces New $250 Million Share Repurchase Authorization

Taro Announces New $250 Million Share Repurchase Authorization

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that its Board of Directors has approved a new $250 million share repurchase authorization of its ordinary shares.

Sun's Taro Unit Names New CEO Amid Generics Investigation

Sun's Taro Unit Names New CEO Amid Generics Investigation

The India pharma giant also purchases an 85.1% interest in Biosintez for $60 million.

TARO SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Taro Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of December 27, 2016

TARO SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Taro Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries Ltd.

Taro Announces Appointment Of New CEO And New Board Member Nominations

Taro Announces Appointment Of New CEO And New Board Member Nominations

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today the appointment of Mr.

Generics Fuel Solid 3Q for Taro Pharmaceutical

Generics Fuel Solid 3Q for Taro Pharmaceutical

Days after price fixing allegations go public over generic drugs, Taro posts financials showing net sales up thanks to, yes that's right, its U.S. generic drug business.

Taro Provides Results For September 30, 2016

Taro Provides Results For September 30, 2016

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and six months ended September 30, 2016.

After Big Drop in Generics, Ride the Rebound

After Big Drop in Generics, Ride the Rebound

Investors have a buying opportunity because the damage by any criminal charges is far less than what is likely to be inflicted by the feds.

Generics Hit by Report on Pending DOJ Price Fixing Charges

Generics Hit by Report on Pending DOJ Price Fixing Charges

The DOJ's investigation has been under way for at least two years and a number of companies have reported receiving subpoenas related to the investigation.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Taro Pharmaceutical Industries Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Taro Pharmaceutical Industries Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. - TARO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. - TARO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Taro Pharmaceutical Industries Ltd.

Taro To Announce Second Quarter Results On November 8, 2016

Taro To Announce Second Quarter Results On November 8, 2016

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2016, on Tuesday, November 8, 2016.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Taro Pharmaceutical Industries Ltd. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Taro Pharmaceutical Industries Ltd.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Taro Pharmaceutical Industries Ltd. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Taro Pharmaceutical Industries Ltd. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Taro Pharmaceutical Industries Ltd.

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Taro Pharmaceutical Industries Ltd. And Advises Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Taro Pharmaceutical Industries Ltd. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC announces that it is investigating Taro Pharmaceutical Industries Ltd.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Taro Pharmaceutical Industries Ltd. - TARO

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Taro Pharmaceutical Industries Ltd. - TARO

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Taro Pharmaceutical Industries Ltd.

Taro Appoints New Chief Financial Officer

Taro Appoints New Chief Financial Officer

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced the appointment of Mariano Balaguer as Vice President, CFO and Chief Accounting Officer, effective today.

Taro Announces Completion Of $250 Million Share Repurchase Program

Taro Announces Completion Of $250 Million Share Repurchase Program

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it recently completed its $250 million share repurchase program.